predicts risk of recurrence



Know your risk of breast cancer recurrence with CanAssist Breast

What is CanAssist Breast?

CanAssist Breast (CAB) is a prognostic test developed by OncoStem for eligible* breast cancer patients. CAB is performed on patient's tumor sample removed during surgery and provides information about risk of breast cancer recurrence beyond what current conventional methods can offer. CAB determines whether a patient has "low- or high-risk" of breast cancer recurrence, which helps oncologists in deciding use of chemotherapy and/or additional therapies.

CanAssist Breast is offered as a service from OncoStem's CAP, ISO15189 and ISO13485 accredited laboratory in Bangalore, India.

CanAssist Breast Offered as a Service:-

Eligible breast cancer patients



Paraffin block of tumor removed by surgery



Sent to OncoStem Diagnostics



OncoStem to perform CAB test •

CAB report is sent to doctors and patients within 8 Working Days

What makes CAB unique?



First test to be developed and validated on Asian patients



Large Indian and international validation cohort



Machine Learning-based algorithm



Renowned validation partners in India, USA and Europe



Patented combination of biomarkers



CAP accredited ISO 13485 accredited ISO 15189 accredited



Publisted & presented in major international journals & conferences

CanAssist Breast's Machine Learning algorithm answers key questions any breast cancer patient may have.



Will my breast cancer recur in my body?



Do I need chemotherapy?

